Ferric ion-mediated biomimetic mineralization of human serum albumin with doxorubicin and celastrol for enhanced antitumor therapy.

Jie Liu, Jun Chen, Lei Zhang, Chunyong Xia

Abstract read

In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jie LiuDepartment of Pharmacy, Chongqing University Jiangjin Hospital, No. 728, Dingshan Street, Jiangjin, Chongqing, 402260, China.

Jun ChenDepartment of Pediatrics, Chongqing Health Center for Women and Children, Chongqing, China.

Lei ZhangNHC Key Laboratory of Birth Defects and Reproductive Health, Chongqing, China.

Chunyong XiaDepartment of Pharmacy, Chongqing University Jiangjin Hospital, No. 728, Dingshan Street, Jiangjin, Chongqing, 402260, China. 739488865@qq.com.ORCID https://orcid.org/0000-0002-3855-7969

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Doxorubicin (DOX) efficacy in breast cancer is limited by dose-dependent cardiotoxicity and the development of multidrug resistance, while celastrol (Cel) suffers from poor solubility, low bioavailability and systemic toxicity. Their combination offers synergistic potential, but effective co-delivery remains challenging. We designed a protein-based nanoplatform via ferric ion-mediated biomimetic mineralization co-assembly of DOX, Cel, and human serum albumin (HSA) for enhanced antitumor therapy. HSA-Fe(III)-Cel-DOX nanoparticles were characterized by dynamic light scattering (DLS) and transmission electron microscopy (TEM). Drug loading and encapsulation efficiencies were determined by high-performance liquid chromatography (HPLC). In vitro drug release was evaluated with or without glutathione (GSH). Cytotoxicity against 4T1 murine breast cancer cells was assessed by CCK-8 assay. The optimized HSA-Fe(III)-Cel-DOX NPs (8 mM Fe

Indexed as

DoxorubicinFerric CompoundsSerum Albumin, HumanTriterpenesAnimalsBiomimeticsBreast NeoplasmsCell Line, TumorCell SurvivalDrug LiberationFemaleGlutathioneHumansMiceNanoparticlesPentacyclic TriterpenescelastrolDoxorubicinFerric CompoundsGlutathionePentacyclic TriterpenesSerum Albumin, HumanTriterpenesBreast cancerCelastrolDoxorubicinFerric ionHuman serum albumin

Identifiers

PMID42365119

DOI10.1016/j.jcis.2024.01.066

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.